UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (Date of earliest event reported): September 29, 2009
The Medicines Company
(Exact Name of Registrant as Specified in Charter)
|
|
|
|
|
Delaware
|
|
000-31191
|
|
04-3324394 |
|
|
|
|
|
(State or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.) |
|
|
|
8 Sylvan Way
Parsippany, New Jersey
|
|
07054 |
|
|
|
(Address of Principal Executive Offices)
|
|
(Zip Code) |
Registrants telephone number, including area code: (973) 290-6000
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the
filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of
Certain Officers; Compensatory Arrangements of Certain Officers
On September 29, 2009, John P. Kelley resigned as President and Chief Operating Officer and as
director of the Company to pursue other interests, effective October 1, 2009. Mr. Kelley will serve
as a Special Advisor to the Companys Chief Executive Officer until the earlier of December 31,
2009 or until he commences other full-time employment. On October 2, 2009, the Company issued a
press release regarding Mr. Kelleys resignation, attached
hereto as Exhibit 99.1.
Item 9.01. Financial Statements and Exhibits
(d) Exhibits
|
|
99.1 |
|
Press release dated October 2, 2009 entitled The Medicines
Company Announces the Resignation of its Chief Operating Officer |